Rheumatoid Arthritis

Evidence-Based Rheumatology

Volumn , Issue , 2009, Pages 243-314

  Suarez Almazor, Maria E ^a   Osiri, Manathip ^b   Emery, Paul ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b CHULALONGKORN UNIVERSITY   (Thailand)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Cochrane Database of Systematic Reviews; COX 2 selective inhibitors and biologic agents; Disease Activity Score (DAS); Disease modifying antirheumatic drugs (DMARDs); HERA Study Group; Low dose oral corticosteroid in RA; Rheumatoid arthritis (RA) chronic inflammatory joint disease; Rheumatoid arthritis and methotrexate (MTX); Side effects with methotrexate; Suboptimal methotrexate response and combination therapy

Indexed keywords

EID: 84889433107     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444315844.ch9     Document Type: Chapter

References (135)

1. Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 2001; 27(2): 269-281.
2. Wilske KR, Healey LA. Remodeling the pyramid-a concept whose time has come. J Rheumatol 1989; 16(5): 565-7.
3. Boers M. Rheumatoid arthritis. Treatment of early disease. Rheum Dis Clin North Am 2001; 27(2): 405-14.
4. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002; 46(2): 328-46.
5. Boers M, Tugwell P, Felson DT, et al. World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol Suppl 1994; 41: 86-9.
6. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38(6): 727-35.
7. van Gestel AM, Anderson JJ, van Riel PL, et al. ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology. J Rheumatol 1999; 26(3): 705-11.
8. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995; 310(6977): 452-4.
9. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988; 318(26): 1728-33.
10. Sackett DL, Straus S, Richardson SW, Rosenberg W, Haynes BR. Therapy. Evidence-based medicine. How to practice and teach EBM, 2nd ed. Edinburgh: Churchill Livingstone, 2000: 105-53.
11. Norman GR, Sridhar FG, Guyatt GH, Walter SD. Relation of distribution-and anchor-based approaches in interpretation of changes in health-related quality of life. Med Care 2001; 39(10): 1039-47.
12. Green M, Marzo-Ortega H, McGonagle D, et al. Persistence of mild, early inflammatory arthritis: the importance of disease duration, rheumatoid factor, and the shared epitope. Arthritis Rheum 1999; 42(10): 2184-8.
13. Emery P, Breedveld FC, Dougados M, Kalden JR, Schiff MH, Smolen JS. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis 2002; 61(4): 290-7.
14. Quinn MA, Conaghan PG, Emery P. The therapeutic approach of early intervention for rheumatoid arthritis: what is the evidence? Rheumatology (Oxford) 2001; 40(11): 1211-20.
15. Tsakonas E, Fitzgerald AA, Fitzcharles MA, et al. Consequences of delayed therapy with second-line agents in rheumatoid arthritis: a 3 year followup on the hydroxychloroquine in early rheumatoid arthritis (HERA study). J Rheumatol 2000; 27(3): 623-9.
16. O'Dell JR, Haire CE, Palmer W, et al. Treatment of early rheumatoid arthritis with minocycline or placebo: results of a randomised, double-blind, placebo-controlled trial. Arthritis Rheum 1997; 40(5): 842-8.
17. Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350(9074): 309-18.
18. Buckland-Wright JC, Clarke GS, Chikanza IC, Grahame R. Quantitative microfocal radiography detects changes in erosion area in patients with early rheumatoid arthritis treated with myocrisine. J Rheumatol 1993; 20(2): 243-7.
19. Egsmose C, Lund B, Borg G, et al. Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. J Rheumatol 1995; 22(12): 2208-13.
20. Munro R, Hampson R, McEntegart A, et al. Improved functional outcome in patients with early rheumatoid arthritis treated with intramuscular gold: results of a five year prospective study. Ann Rheum Dis 1998; 57(2): 88-93.
21. van der Heide A, Jacobs JW, Bijlsma JW, et al. The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomised, controlled trial. Ann Intern Med 1996; 124(8): 699-707.
22. Landewe RB, Boers M, Verhoeven AC, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002; 46(2): 347-56.
23. Lard LR, Visser H, Speyer I, et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001; 111(6): 446-51.
24. Lard LR, Boers M, Verhoeven A, et al. Early and aggressive treatment of rheumatoid arthritis patients affects the association of HLA class II antigens with progression of joint damage. Arthritis Rheum 2002; 46(4): 899-905.
25. Möttönen T, Hannonen P, Korpela M, et al. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002; 46(4): 894-8.
26. Suarez-Almazor ME, Belseck E, Shea B, Wells G, Tugwell P. Methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev 2000;(2): CD000957.
27. Emery P, Breedveld FC, Lemmel EM, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000; 39(6): 655-65.
28. Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999; 159(21): 2542-50.
29. Felson DT, Anderson JJ, Meenan RF. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials. Arthritis Rheum 1992; 35(10): 1117-25.
30. Dougados M, Combe B, Cantagrel A, et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis 1999; 58(4): 220-5.
31. Haagsma CJ, van Riel PL, de Jong AJ, van de Putte LB. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomised, controlled, double-blind, 52 week clinical trial. Br J Rheumatol 1997; 36(10): 1082-8.
32. Hamilton J, McInnes IB, Thomson EA, et al. Comparative study of intramuscular gold and methotrexate in a rheumatoid arthritis population from a socially deprived area. Ann Rheum Dis 2001; 60(6): 566-72.
33. Rau R, Herborn G, Menninger H, Sangha O. Radiographic outcome after three years of patients with early erosive rheumatoid arthritis treated with intramuscular methotrexate or parenteral gold. Extension of a one-year double-blind study in 174 patients. Rheumatology (Oxford) 2002; 41(2): 196-204.
34. Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. Arthritis Rheum 1990; 33(10): 1449-61.
35. Gotzsche PC, Podenphant J, Olesen M, Halberg P. Metaanalysis of second-line antirheumatic drugs: sample size bias and uncertain benefit. J Clin Epidemiol 1992; 45(6): 587-94.
36. Suarez-Almazor ME, Belseck E, Wells G, Shea B, Tugwell P. Meta-analyses of placebo controlled trials of diseasemodifying antirheumatic drugs (DMARD for the treatment of rheumatoid arthritis (RA). Arthritis Rheum 1998; 41: S153.
37. Alarcon GS, Lopez-Mendez A, Walter J, et al. Radiographic evidence of disease progression in methotrexate treated and nonmethotrexate disease modifying antirheumatic drug treated rheumatoid arthritis patients: a meta-analysis. J Rheumatol 1992; 19(12): 1868-73.
38. Maetzel A, Wong A, Strand V, Tugwell P, Wells G, Bombardier C. Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatology (Oxford) 2000; 39(9): 975-81.
39. Ortiz Z, Shea B, Suarez-Almazor ME, Moher D, Wells GA, Tugwell P. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomised controlled trials. J Rheumatol 1998; 25(1): 36-43.
40. Beauparlant P, Papp K, Haraoui B. The incidence of cancer associated with the treatment of rheumatoid arthritis. Semin Arthritis Rheum 1999; 29(3): 148-58.
41. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359(9313): 1173-7.
42. Guidelines for monitoring drug therapy in rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum 1996; 39(5): 723-31.
43. Suarez-Almazor ME, Belseck E, Shea B, Wells G, Tugwell P. Sulfasalazine for rheumatoid arthritis. Cochrane Database Syst Rev 2000;(2): CD000958.
44. Weinblatt ME, Reda D, Henderson W, et al. Sulfasalazine treatment for rheumatoid arthritis: a metaanalysis of 15 randomised trials. J Rheumatol 1999; 26(10): 2123-30.
45. Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a doubleblind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999; 353(9149): 259-66.
46. van der Heijde DM, van Riel PL, Nuver-Zwart IH, Gribnau FW, vad de Putte LB. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989; 1(8646): 1036-8.
47. Capell HA, Maiden N, Madhok R, Hampson R, Thomson EA. Intention-to-treat analysis of 200 patients with rheumatoid arthritis 12 years after random allocation to either sulfasalazine or penicillamine. J Rheumatol 1998; 25(10): 1880-6.
48. Suarez-Almazor ME, Belseck E, Shea B, Homik J, Wells G, Tugwell P. Antimalarials for treating rheumatoid arthritis. Cochrane Database Syst Rev 2000;(4): CD000959.
49. Scull E. Chloroquine and hydroxychloroquine therapy in rheumatoid arthritis. Arthritis Rheum 1962; 5: 30-6.
50. Finbloom DS, Silver K, Newsome DA, Gunkel R. Comparison of hydroxychloroquine and chloroquine use and the development of retinal toxicity. J Rheumatol 1985; 12(4): 692-4.
51. Esdaile JM, Suissa S, Shiroky JB, et al. A randomised trial of hydroxychloroquine in early rheumatoid arthritis: the HERA study. Am J Med 1995; 98: 156-68.
52. Jessop JD, O'Sullivan MM, Lewis PA, et al. A long-term five-year randomised controlled trial of hydroxychloroquine, sodium aurothiomalate, auranofin and penicillamine in the treatment of patients with rheumatoid arthritis. Br J Rheumatol 1998; 37(9): 992-1002.
53. Clark P, Tugwell P, Bennet K, et al. Injectable gold for rheumatoid arthritis. Cochrane Database Syst Rev 2000;(2): CD000520.
54. Rau R. Does parenteral gold retard radiological progression in rheumatoid arthritis? Z Rheumatol 1996; 55: 307-18.
55. Kvien TK, Zeidler HK, Hannonen P, et al. Long term efficacy and safety of cyclosporin versus parenteral gold in early rheumatoid arthritis: a three year study of radiographic progression, renal function, and arterial hypertension. Ann Rheum Dis 2002; 61: 511-16.
56. Suarez-Almazor ME, Spooner C, Belseck E. Penicillamine for rheumatoid arthritis. Cochrane Database Syst Rev 2000;(2): CD001460.
57. Hewitson PJ, Debroe S, McBride A, Milne R. Leflunomide and rheumatoid arthritis: a systematic review of effectiveness, safety and cost implications. J Clin Pharm Ther 2000; 25(4): 295-302.
58. Osiri M, Shea B, Robinson V, et al. Leflunomide for treating rheumatoid arthritis. Cochrane Database Syst Rev 2003;(1): CD002047.
59. Mladenovic V, Domljan Z, Rozman B, et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomised, placebo-controlled, phase II study. Arthritis Rheum 1995; 38(11): 1595-603.
60. Scott DL, Smolen JS, Kalden JR, et al. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis 2001; 60(10): 913-23.
61. Cohen S, Cannon GW, Schiff M, et al. Two-year, blinded, randomised, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis Rheum 2001; 44(9): 1984-92.
62. Wells G, Haguenauer D, Shea B, et al. Cyclosporin for rheumatoid arthritis. The Cochrane Library [3]. 2000. Cochrane Database Syst Rev 2000;(3): CD00846.
63. Suarez-Almazor ME, Spooner C, Belseck E. Azathioprine for rheumatoid arthritis. Cochrane Database Syst Rev 2000;(2): CD001461.
64. Suarez-Almazor ME, Belseck E, Shea B, Wells G, Tugwell P. Cyclophosphamide for rheumatoid arthritis. Cochrane Database Syst Rev 2000;(2): CD001157.
65. Radis CD, Kahl LE, Baker GL, et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum 1995; 38(8): 1120-7.
66. Kloppenburg M, Breedveld FC, Terwiel JP, Mallee C, Dijkmans BA. Minocycline in active rheumatoid arthritis. A double-blind, placebo-controlled trial. Arthritis Rheum 1994; 37(5): 629-36.
67. Tilley BC, Alarcon GS, Heyse SP, et al. Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebocontrolled trial. MIRA Trial Group. Ann Intern Med 1995; 122(2): 81-9.
68. O'Dell JR, Blakely KW, Mallek JA, et al. Treatment of early seropositive rheumatoid arthritis: a two-year, double-blind comparison of minocycline and hydroxychloroquine. Arthritis Rheum 2001; 44(10): 2235-41.
69. Suarez-Almazor ME, Spooner CH, Belseck E, Shea B. Auranofin versus placebo in rheumatoid arthritis. Cochrane Database Syst Rev 2000;(2): CD002048.
70. McEntegart A, Porter D, Capell HA, Thomson EA. Sulfasalazine has a better efficacy/toxicity profile than auranofin-evidence from a 5 year prospective, randomised trial. J Rheumatol 1996; 23(11): 1887-90.
71. Singh G, Fries JF, Williams CA, Zatarain E, Spitz P, Bloch DA. Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis. J Rheumatol 1991; 18(2): 188-94.
72. Osiri M, Suarez-Almazor M, Wells G, Robinson V, Tugwell P. Number needed to treat (NNT): Implication in Rheumatology Clinical Practice. Ann Rheum Dis 2003; 62(4): 316-21
73. van der Heijde DM. Joint erosions and patients with early rheumatoid arthritis. Br J Rheumatol 1995; 34 Suppl 2: 74-8.
74. Borg G, Allander E, Berg E, Brodin U, From A, Trang L. Auranofin treatment in early rheumatoid arthritis may postpone early retirement. Results from a 2-year double blind trial. J Rheumatol 1991; 18(7): 1015-20.
75. Davis MJ, Dawes PT, Fowler PD, Clarke S, Fisher J, Shadforth MF. Should disease-modifying agents be used in mild rheumatoid arthritis? Br J Rheumatol 1991; 30(6): 451-4.
76. Hannonen P, Mottonen T, Hakola M, Oka M. Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study. Arthritis Rheum 1993; 36(11): 1501-9.
77. van Jaarsveld CH, Jacobs JW, van der Veen MJ, et al. Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial. On behalf of the Rheumatic Research Foundation Utrecht, The Netherlands. Ann Rheum Dis 2000; 59(6): 468-77.
78. Rau R, Herborn G, Menninger H, Blechschmidt J. Comparison of intramuscular methotrexate and gold sodium thiomalate in the treatment of early erosive rheumatoid arthritis: 12 month data of a double-blind parallel study of 174 patients. Br J Rheumatol 1997; 36(3): 345-52.
79. Sulfasalazine in early rheumatoid arthritis. The Australian Multicentre Clinical Trial Group. J Rheumatol 1992; 19(11): 1672-7.
80. Verhoeven AC, Boers M, Tugwell P. Combination therapy in rheumatoid arthritis: updated systematic review. Br J Rheumatol 1998; 37(6): 612-19.
81. Felson DT, Anderson JJ, Meenan RF. The efficacy and toxicity of combination therapy in rheumatoid arthritis. A meta-analysis. Arthritis Rheum 1994; 37(10): 1487-91.
82. Calguneri M, Pay S, Caliskaner Z, et al. Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis. Clin Exp Rheumatol 1999; 17(6): 699-704.
83. Möttönen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999; 353(9164): 1568-73.
84. O'Dell JR, Haire CE, Erikson N, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996; 334(20): 1287-91.
85. Proudman SM, Conaghan PG, Richardson C, Griffiths B, Green MJ, McGonagle D et al. Treatment of poorprognosis early rheumatoid arthritis. A randomised study of treatment with methotrexate, cyclosporin A, and intraarticular corticosteroids compared with sulfasalazine alone. Arthritis Rheum 2000; 43(8): 1809-19.
86. van den Borne BE, Landewe RB, Goei The HS, et al. Combination therapy in recent onset rheumatoid arthritis: a randomised double blind trial of the addition of low dose cyclosporine to patients treated with low dose chloroquine. J Rheumatol 1998; 25(8): 1493-8.
87. O'Dell JR, Leff R, Paulsen G, et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomised, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46(5): 1164-70.
88. Ferraccioli GF, Gremese E, Tomietto P, et al. Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years. Rheumatology (Oxford) S2002; 41(8): 892-8.
89. Marchesoni A, Battafarano N, Arreghini M, et al. Stepdown approach using either cyclosporin A or methotrexate as maintenance therapy in early rheumatoid arthritis. Arthritis Rheum 2002; 47(1): 59-66.
90. Blumenauer B, Judd M, Wells G, et al. Infliximab for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev 2002;(3): CD003785.
91. Rau R. Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials. Ann Rheum Dis 2002; 61 Suppl 2: ii70-ii73.
92. Calabrese LH. Anakinra treatment of patients with rheumatoid arthritis. Ann Pharmacother 2002; 36(7-8): 1204-9.
93. Reneses S, Pestana L. (Systematic review of clinical trials on the treatment of rheumatoid arthritis with tumour necrosis factor alpha inhibitors.) Med Clin (Barc) 2001; 116(16): 620-8.
94. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomised, controlled trial. Ann Intern Med 1999; 130(6): 478-86.
95. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340(4): 253-9.
96. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343(22): 1586-93.
97. Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002; 46(6): 1443-50.
98. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41(9): 1552-63.
99. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha) monoclonal antibody versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354(9194): 1932-9.
100. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2 versus placebo in rheumatoid arthritis). Lancet 1994; 344(8930): 1105-10.
101. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343(22): 1594-602.
102. den Broeder A, van de PL, Rau R, et al. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7)in patients with rheumatoid arthritis. J Rheumatol 2002; 29(11): 2288-98.
103. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48(1): 35-45.
104. Campion GV, Lebsack ME, Lookabaugh J, et al. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group. Arthritis Rheum 1996; 39(7): 1092-101.
105. Drevlow BE, Lovis R, Haag MA, et al. Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum 1996; 39(2): 257-65.
106. Jiang Y, Genant HK, Watt I, et al. A multicenter, doubleblind, dose-ranging, randomised, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000; 43(5): 1001-9.
107. Cohen S, Hurd E, Cush J, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomised, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46(3): 614-24.
108. Nuki G, Bresnihan B, Bear MB, McCabe D. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomised, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46(11): 2838-46.
109. Gotzsche PC, Johansen HK. Meta-analysis of short-term low dose prednisolone versus placebo and nonsteroidal anti-inflammatory drugs in rheumatoid arthritis. BMJ 1998; 316(7134): 811-18.
110. Criswell LA, Saag KG, Sems KM, et al. Moderate-term, low-dose corticosteroids for rheumatoid arthritis. Cochrane Database Syst Rev 2000;(2): CD001158.
111. Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 1995; 333(3): 142-6.
112. Hickling P, Jacoby RK, Kirwan JR. Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group. Br J Rheumatol 1998; 37(9): 930-6.
113. Van Everdingen AA, Jacobs JW, Van Reesema DRS, et al. Low-dose prednisolone therapy for patients with early active rheumatoid arthritis. Ann Intern Med 2002; 136: 1-12.
114. Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994; 37(4): 481-94.
115. Verhoeven AC, Boers M. Limited bone loss due to corticosteroids; a systematic review of prospective studies in rheumatoid arthritis and other diseases. J Rheumatol 1997; 24(8): 1495-503.
116. Garner S, Fidan D, Frankish R, et al. Celecoxib for rheumatoid arthritis. Cochrane Database Syst Rev 2003;(4): CD003831.
117. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomised controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284(10): 1247-55.
118. Garner S, Fidan D, Frankish R, et al. Rofecoxib for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev 2002;(3): CD003685.
119. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343(21): 1520-8.
120. Schnitzer TJ, Truitt K, Fleischmann R, et al. The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group. Clin Ther 1999; 21(10): 1688-702.
121. Riemsma RP, Kirwan JR, Taal E, Rasker JJ. Patient education for adults with rheumatoid arthritis. Cochrane Database Syst Rev 2002;(3): CD003688.
122. Badamgarav E, Croft JD, Hohlbauch A, et al. Effectiveness of disease management programs in rheumatoid arthritis. Arthritis Rheum 2003; 49(3): 377-87.
123. Casimiro L, Brosseau L, Milne S, Robinson V, Wells G, Tugwell P. Acupuncture and electroacupuncture for the treatment of RA. Cochrane Database Syst Rev 2002;(3): CD003788.
124. Casimiro L, Brosseau L, Robinson V, et al. Therapeutic ultrasound for the treatment of rheumatoid arthritis. Cochrane Database Systematic Review 2002;(3): CD003787.
125. Robinson V, Brosseau L, Casimiro L, et al. Thermotherapy for treating rheumatoid arthritis. Cochrane Database Syst Rev 2002;(2): CD002826.
126. Brosseau LU, Pelland LU, Casimiro LY, Robinson VI, Tugwell PE, Wells GE. Electrical stimulation for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev 2002;(2): CD003687.
127. Van Den Ende CH, Vliet Vlieland TP, Munneke M, Hazes JM. Dynamic exercise therapy for rheumatoid arthritis. Cochrane Database Syst Rev 2000;(2): CD000322.
128. Hochberg MC, Tracy JK, Flores RH. "Stepping-up" from methotrexate: a systematic review of randomised placebo controlled trials in patients with rheumatoid arthritis with an incomplete response to methotrexate. Ann Rheum Dis 2001; 60 Suppl 3: iii51-iii54.
129. Hawley DJ, Wolfe F. Are the results of controlled clinical trials and observational studies of second line therapy in rheumatoid arthritis valid and generalizable as measures of rheumatoid arthritis outcome: analysis of 122 studies. J Rheumatol 1991; 18(7): 1008-14.
130. ten Wolde S, Breedveld FC, Hermans J, et al. Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet 1996; 347(8998): 347-52.
131. Sander O, Herborn G, Bock E, Rau R. Prospective six year follow up of patients withdrawn from a randomised study comparing parenteral gold salt and methotrexate. Ann Rheum Dis 1999; 58(5): 281-7.
132. Williams HJ, Willkens RF, Samuelson CO, Jr., Alarcon GS, Guttadauria M, Yarboro C et al. Comparison of lowdose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 1985; 28(7): 721-30.
133. Ward JR, Williams HJ, Egger MJ, et al. Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 1983; 26(11): 1303-15.
134. Townes AS, Sowa JM, Shulman LE. Controlled trial of cyclophosphamide in rheumatoid arthritis. Arthritis Rheum 1976; 19(3): 563-73.
135. Williams HJ, Ward JR, Reading JC, et al. Low-dose Dpenicillamine therapy in rheumatoid arthritis. A controlled, double-blind clinical trial. Arthritis Rheum 1983; 26(5): 581-92.